Breast Cancer SPORE Developmental Research Program
The Mayo Clinic Breast Cancer SPORE strives to establish innovative, high-quality projects in the Developmental Research Program that generate results that can be translated into clinical applications. New ideas may emerge from the laboratory that need to be tested in a clinical setting. And in many instances, clinical practice has findings that need to be further developed in the laboratory. The Developmental Research Program engages this cycle of interaction between research discoveries and clinical practice.
Developmental Research Program awards are given for innovative laboratory, population and clinical study proposals that include interdisciplinary collaboration and demonstrate the potential to generate new hypotheses that can be tested in larger-scale research projects or clinical trials.
Novel research is imperative in a field where a cure is yet to be found. The availability of developmental research support provides a stimulus for creativity, a vehicle for encouraging the interaction of basic scientists and translational investigators, and an opportunity for expanding the research spectrum of the Mayo Clinic Breast Cancer SPORE.
Developmental Research Program awards
After a Mayo Clinic-wide competition, six Breast Cancer SPORE Developmental Research Program awards were made in September 2011. Each of these awards was for one year, with anticipation of a second year of funding based on demonstration of adequate progress. Expectations of these projects are that they will develop sufficient preliminary data for a successful R01-level grant application by the completion of the two years of funding and that they have the potential for progression to a full project within the Breast Cancer SPORE.
Breast Cancer SPORE Developmental Research Program projects
|Zhenkun Lou, Ph.D.
||The role of UHRF1 in BRCA1 regulation and breast cancer pathogenesis|
|Georges Mer, Ph.D.
||Design and characterization of 53BP1 inhibitors as potential anti-tumor compounds for breast cancer therapy|
|Larry R. Pease, Ph.D.
||Mechanisms of genome evolution in spontaneous breast cancer|
|Evette Radisky, Ph.D.
||Development of highly selective MMP-9 inhibitors for breast cancer therapy|
|Celine M. Vachon, Ph.D.
||MRI-density and morphologic measures and breast cancer among high-risk women|
|Jan van Deursen, Ph.D.
||Bub1-mediated aurora B activation in breast cancer tumor development and aggressiveness|